Evidence map›Paper›PMID 37763192›Full record

ArticleJournal of personalized medicine2023

Correction: Noguchi et al. Establishment and Characterization of NCC-PMP1-C1: A Novel Patient-Derived Cell Line of Metastatic Pseudomyxoma Peritonei.

Rei Noguchi, Yuki Yoshimatsu, Yooksil Sin, Takuya Ono, Ryuto Tsuchiya, Hiroshi Yoshida, Tohru Kiyono, Yutaka Yonemura, Tadashi Kondo

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of personalized medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Rei NoguchiDivision of Rare Cancer Research, National Cancer Center Research Institute, Tokyo 104-0045, Japan.ORCID 0000-0003-1180-2394
Yuki YoshimatsuDivision of Rare Cancer Research, National Cancer Center Research Institute, Tokyo 104-0045, Japan.
Yooksil SinDivision of Rare Cancer Research, National Cancer Center Research Institute, Tokyo 104-0045, Japan.
Takuya OnoDivision of Rare Cancer Research, National Cancer Center Research Institute, Tokyo 104-0045, Japan.
Ryuto TsuchiyaDivision of Rare Cancer Research, National Cancer Center Research Institute, Tokyo 104-0045, Japan.
Hiroshi YoshidaDepartment of Diagnostic Pathology, National Cancer Center Hospital, Tokyo 104-0045, Japan.ORCID 0000-0002-7569-7813
Tohru KiyonoExploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa 277-8577, Japan.ORCID 0000-0003-1769-403X
Yutaka YonemuraNPO to Support Peritoneal Surface Malignancy Treatment, Japanese/Asian School of Peritoneal Surface Oncology, Kyoto 600-8189, Japan.
Tadashi KondoDivision of Rare Cancer Research, National Cancer Center Research Institute, Tokyo 104-0045, Japan.ORCID 0000-0001-6405-7792

Funding

Japan Society for the Promotion of Science 21K08743
6 · The paper itself

Abstract

There was an error in the original publication [...].

Identifiers

PMID37763192
PMCPMC10533008

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.